Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short term Debt (2021 - 2024)

Historic Short term Debt for Standard Biotools (LAB) over the last 7 years, with Q3 2024 value amounting to $54.9 million.

  • Standard Biotools' Short term Debt rose 99826.0% to $54.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $54.9 million, marking a year-over-year increase of 99826.0%. This contributed to the annual value of $54.5 million for FY2023, which is 251785.89% up from last year.
  • According to the latest figures from Q3 2024, Standard Biotools' Short term Debt is $54.9 million, which was up 99826.0% from $54.8 million recorded in Q2 2024.
  • Over the past 5 years, Standard Biotools' Short term Debt peaked at $54.9 million during Q3 2024, and registered a low of $833000.0 during Q3 2022.
  • Moreover, its 4-year median value for Short term Debt was $5.9 million (2021), whereas its average is $24.2 million.
  • Per our database at Business Quant, Standard Biotools' Short term Debt crashed by 6953.79% in 2022 and then soared by 251785.89% in 2023.
  • Over the past 4 years, Standard Biotools' Short term Debt (Quarter) stood at $6.8 million in 2021, then plummeted by 69.54% to $2.1 million in 2022, then surged by 2517.86% to $54.5 million in 2023, then rose by 0.7% to $54.9 million in 2024.
  • Its last three reported values are $54.9 million in Q3 2024, $54.8 million for Q2 2024, and $54.7 million during Q1 2024.